Comparison
Buserelin vs. Linaclotid
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Research other
Research other
CAS no.
57982-77-1
851199-59-2
Molecular weight
1239.42 g/mol
1526.74 g/mol
Half-life
no data
no data
Sequence
no data
no data
Mechanism of action
Buserelin
Buserelin is a potent GnRH agonist: after an initial stimulatory surge ('flare'), continuous receptor occupancy causes downregulation and thereby suppression of LH, FSH and the downstream sex hormones.
Linaclotid
Linaclotide activates the guanylate cyclase-C receptor on the luminal surface of the intestinal epithelium. This raises cyclic GMP (cGMP), increases secretion of chloride and bicarbonate into the lumen, raises stool fluid content and accelerates transit; pain signaling is also modulated.
Evidence base
Highest evidence
Human RCT
Human RCT
Studies
0
0
of which in humans
0
0
Effects recorded
2
2
Open conflicts
0
0
Documented adverse events
1
1
Legal status
Full entries
Frequently asked questions
- What is the difference between Buserelin and Linaclotid?
- Buserelin is classified as "Research other", while Linaclotid is classified as "Research other". Buserelin: Buserelin is a synthetic GnRH agonist (including as a nasal spray). It is used in endometriosis, hormone-dependent prostate cancer and assisted reproduction; approved in Europe (Suprefact), not in the US. Linaclotid: Linaclotide is a 14-amino-acid peptide and guanylate cyclase-C (GC-C) agonist. It is approved for irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, Buserelin or Linaclotid?
- The highest available evidence level is "Human RCT" for Buserelin and "Human RCT" for Linaclotid. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of Buserelin and Linaclotid in Germany and the United States?
- Germany: Buserelin — Prescription, Linaclotid — Prescription. United States: Buserelin — Unapproved, Linaclotid — Prescription. These are factual summaries with source and review date on the individual pages.